| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th January 2020 | Edward F Smith | 2,380 | Open or private sale | $2.05 | $4,879.00 |
| 10th January 2020 | Scott Braunstein | 26,500 | Grant/award etc. | $0.00 | |
| 31st December 2019 | Scott Braunstein | 31,780 | Grant/award etc. | $0.00 | |
| 13th December 2019 | Scott Braunstein | 100,000 | Open or private purchase | $1.25 | $125,000.00 |
| 29th May 2019 | Scott Braunstein | 4,967 | Grant/award etc. | $0.00 | |
| 16th May 2019 | Edward F Smith | 24,211 | Open or private sale | $5.03 | $121,781.33 |
| 18th March 2019 | Christopher Michael Cashman | 31,662 | Exercise of derivative | $1.04 | $32,928.48 |
| 29th January 2019 | Edward F Smith | 2,492 | Open or private sale | $3.06 | $7,625.52 |
| 28th January 2019 | Christopher Michael Cashman | 8,142 | Open or private sale | $3.13 | $25,484.46 |
Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw in 2003.
Ticker: MRNS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1267813
Employees: 40
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $99 M (8%)
Assets, Current: $109 M (15%)
Property, Plant and Equipment, Net: $2 M (-7%)
Other Assets, Noncurrent: $2 M (-5%)
Assets: $113 M (14%)
Accounts Payable, Current: $4 M (35%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $10 M (18%)
Liabilities: $12 M (11%)
Common Stock, Value, Issued: $123 Th (41%)
Common Stock, Shares, Issued: $122 M (41%)
Retained Earnings (Accumulated Deficit): $279 M (0%)
Treasury Stock, Shares: $292 Th (0%)
Stockholders' Equity (Parent): $101 M (0%)
Liabilities and Equity: $113 M (14%)
Research and Development: $12 M (-56%)
General and Administrative Expenses: $4 M (-48%)
Operating Income/Loss: $16 M (-54%)
